Global Cardiac Troponin Market - 2022-2029

Global Cardiac Troponin Market - 2022-2029

Market Overview

The global cardiac troponin market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 13.2% during the forecast period (2022-2029).

Cardiac troponin generally is a test that detects damage to the heart muscle. Troponin is a protein that occurs in the blood only when the heart muscle is damaged, as in a heart attack. Other reasons for elevated troponin exist, but a heart attack is the most familiar. The test does not measure the low amounts of troponin normally in blood. Troponin T is highly sensitive (hs-TnT) and has been used for advanced tests.

Market Dynamics

The global cardiac troponin market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of cardiovascular patients, improving patient awareness, and rising patient healthcare expenditure.

An increasing prevalence of cardiovascular disease drives the market growth

The rising awareness of the cardiovascular disease and healthcare infrastructure drive the global market. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. Rising patients with the disease need to diagnose the disease drives the market.

Cardiac troponin is an identified biomarker that can impact a change in the care of a patient with acute coronary syndrome. Troponin protein is released from damaged heart muscle into the bloodstream. New high-sensitivity blood tests allow the detection of a very low troponin level soon after the onset of symptoms. The electrocardiogram (ECG) measures the heart’s electrical activity and can show abnormalities in a heart attack.

In addition, the market players are adopting the market strategies such as collaboration and product launches. For instance, in June 2022, LumiraDx Limited announced the diversification of its portfolio with a CE Mark for its D-Dimer test and NT-proBNP test. The commercialization of the latter is projected by the end of 2022, which is expected to facilitate clinical decision-making.

The side effects associated with cardiac troponin will hamper the growth of the market

However, limited specificity and side effects associated with cardiac troponin or biomarkers such as skeletal injury hinder the market growth.

COVID-19 Impact Analysis

The impact of COVID-19 is significant effected on the global cardiac troponin market. As per the article published in Nature Reviews Cardiology in October 2021, cardiovascular complications in patients with moderate-to-severe COVID-19 and evidence of cardiac injury (elevated troponin levels and reduced left ventricular ejection fraction. Patients with preexisting cardiovascular disease may be more susceptible to COVID-19 infection. They may be at increased risk of death, especially when patients present with elevated troponin T levels, where mortality may be three-fold higher than those without cardiovascular disease patients.

Also, those with COVID-19 may be at risk of developing cardiac complications, especially acute cardiac injury and arrhythmias; acute myocardial injury may be more common in patients with preexisting cardiovascular disease and associated with increased morbidity and mortality.

On the other hand, according to the American College of Cardiology, in 2020, the frequency and non-specific nature of abnormal troponin results among patients with COVID-19 infection, clinicians are suggested to only measure troponin if the diagnosis of acute MI is being evaluated in clinical environments. Without supporting evidence, an abnormal troponin should not be supposed to be evidence for an acute MI.

Segment Analysis

The point of care testing segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The point of care testing segment accounts for the largest market share. The rising adoption of point-of-care testing systems for health records is expected to boost the market over the forecast period. As per the article published in Practical Laboratory Medicine in November 2020, Accreditation and regulatory standards highlight the rising need to integrate POC Testing results into the patient’s electric medical records. This promotes accessibility of POCT results, the ability to monitor and trend, prevents unnecessary repeat testing and provides evidence for patient outcomes. As POCT results are used to make clinical decisions, it is important to document results with associated reference intervals, units of measurements, critical values if applicable, date and time of testing, and also be traceable to device serial number, operator identification number, reagent lot number, and quality control (QC) results. POCT results should also be clearly differentiated from other central laboratory results to avoid confusion and trending results from different analytical methodologies. POCT is currently routine in all hospitals and has become the standard for patient care in a variety of other health care settings. Cardiac troponin is accurately performed by POCT.

Geographical Analysis

North America region holds the largest market share of the global cardiac troponin market

North America dominates the market for cardiac troponin and is expected to show a similar trend over the forecast period. The market is driven by the factors such as increasing demand for diagnosis of cardiac disease and advancements in cardiac biomarkers.

As per the Centers for Disease Control and Prevention, 2020, in the United States about 20.1 million adults age 20 and older have CAD (about 7.2%). The rising the patients with cardiovascular disease leads to increasing demand for the market in the region which drives the market in the region.

In addition, the market players are offers the products in the United States region. For instance, Quidel Corporation provides TriageTrueTM High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be indicated as an aid in the diagnosis of myocardial infarction (MI) for use with Quidel’s Triage MeterPro instrumented system.

Competitive Landscape

The cardiac troponin market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Biomerieux, Beckman Coulter, Siemens Healthcare, Roche, Fujirebio, Abbott, LifeSign, Alere, and Singulex, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the cardiac troponin market globally.

For instance,

In April 2021, Roche announced a series of five new intended uses for two key cardiac biomarkers (cTnT-hs), using the Elecsys technology, which has the NT-proBNP and highly sensitive cardiac troponin T.

Biomerieux

Overview:

Biomerieux is a French multinational biotechnology organization founded in 1963 and headquartered in France. It offers innovative products and services to meet the need for global solutions.

Product Portfolio:

VIDAS High sensitive Troponin I: It is a useful aid to optimize the management of Acute Coronary Syndromes (ACS). It provides a high level of performance for diagnosis and risk stratification and delivers a diagnosis within 2 hours.

The global Cardiac Troponin market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.